Mineralys Therapeutics (MLYS) Announces Proposed $250M Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
March 10, 2025 4:03 PM EDTGoldman Sachs analyst Richard Law reiterated a Buy rating and $24.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)
The analyst comments "Earlier this morning, MLYS presented positive topline data for lorundrostat's pivotal Ph. 3 Launch-HTN and Ph. 2 Advance-HTN studies in 3/4L uncontrolled and resistant hypertension (uHTN/rHTN). Launch-HTN met its primary endpoint, with placebo-adjusted SBP reductions of 9.1 mmHg (16.9 mmHg absolute)... More
